This study identified what we believe to be a previously unrecognized pathway, TGF-β/miR-181b/Sema3A/LIMK/p-cofilin, and characterized miR-181b and Sema3A as potential therapeutic targets for the treatment and prevention of AF. This evidence concerns the gene SEMA3A and atrial fibrillation.